Economic costs of hemophilia and the impact of prophylactic treatment on patient management.
Hemophilia is a rare congenital bleeding disorder characterized by spontaneous and potentially life-threatening bleeding episodes. In addition to its clinical burden on the patient, the condition also places a significant economic burden on healthcare payers, patients/caregivers, and society. Hemophilia is associated with staggering direct costs from hospitalizations, outpatient visits, and drug treatments, as well as high indirect costs from diminished work productivity and absenteeism from work and school. Additionally, hemophilia incurs tremendous intangible costs, including reduced quality of life, pain and suffering, and the emotional and physical toll on the patient and caregivers. The evolution of treatment patterns in hemophilia has transformed the once-fatal disease into a chronic but potentially well-managed condition through the use of prophylaxis treatment. However, other complications, such as development of inhibitory antibodies, have added to the complexity of managing the disease and its costs. To ensure optimal treatment outcomes and disease management, there is a critical need to understand the utilization of healthcare resources in the treatment of hemophilia and to educate patients on the importance of treatment adherence and compliance to reduce long-term effects on musculoskeletal health.
sheh-li.chen@unchealth.unc.edu.
Sheh-Li
SL
Chen
D000293:Adolescent; D002648:Child; D017281:Cost of Illness; D005169:Factor VIII / Q000191:economics* / Q000627:therapeutic use; D005260:Female; D017048:Health Care Costs; D006467:Hemophilia A / Q000188:drug therapy / Q000191:economics / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008329:Managed Care Programs / Q000191:economics*; D011322:Primary Prevention / Q000191:economics*; D011788:Quality of Life; D018570:Risk Assessment; D055815:Young Adult
D005169:Factor VIII